Advertisement
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Two weeks ago Vertex spent nearly $1bn on Semma Therapeutics, one of a handful of groups attempting to cure diabetes by implanting patients with shielded islet cells. Sigilon Therapeutics is also active in this area, and is gearing up for its first human trials.
The company also has cell-based therapies in rare disorders heading towards the clinic. The first human trial of its haemophilia A project should get going before the end of the year, while other efforts focus on factor VII deficiency, Fabry disease and mucopolysaccharidosis I.
